Sunrest Lifescience Ltd
Incorporated in 2017, Sunrest Lifescience Ltd trades in Health care and Cosmetics products[1]
- Market Cap ₹ 18.4 Cr.
- Current Price ₹ 43.0
- High / Low ₹ 75.0 / 38.5
- Stock P/E 10.4
- Book Value ₹ 38.8
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.11 times its book value
Cons
- Promoter holding has decreased over last quarter: -16.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 33.41 | |
| 30.38 | |
| Operating Profit | 3.03 |
| OPM % | 9.07% |
| 0.00 | |
| Interest | 0.31 |
| Depreciation | 0.10 |
| Profit before tax | 2.62 |
| Tax % | 23.28% |
| 2.02 | |
| EPS in Rs | 4.68 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 2.92 | |
| -1.15 | |
| -0.33 | |
| Net Cash Flow | 1.45 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Documents
Announcements
-
Voluntary Revision of Financial statements or Report
5 December 2025 - Revised H1 Sep 30, 2025: inventory -166.94L→-266.94L; standalone profit 38.56L→115.68L; consolidated 33.65L→73.36L.
-
Structural Digital Database
21 November 2025 - SDD compliance certificate filed under SEBI PIT Regulations dated 21 Nov 2025.
-
Outcome of Board Meeting
13 November 2025 - Board approved standalone and consolidated unaudited results for half-year ended 30 Sep 2025; revenue ₹3,101.05 lakh, PAT ₹65.35 lakh.
-
Outcome of Board Meeting
13 November 2025 - Board approved standalone and consolidated H1 FY2026 results for period ended 30 Sep 2025; auditor gave unmodified report.
-
Structural Digital Database
10 November 2025 - Filed Structured Digital Database (SDD) compliance certificate as on 04 Nov 2025.
Business Overview:[1][2]
SLSL is in the business of trading of Pharmaceutical Product on wholesale and retail basis. It provides OTC brands in healthcare & personal care viz. Capsules, Tablets, Syrup, Ointment, Gel, mouthwash, Solution, Suspension, Dry Powders, and Toothpaste